August 17 Biotech Update

There is nothing to dissuade me that risk on is creeping back into the market as North Korea is fading into the background (for how long who knows but that is the current trend). As such, this will generally be good for the sector but we are approaching some seasonally weak periods for the market […]

August 4 Biotech Update

I am back from my last trip of the summer and to be honest it is going to take me the weekend to catch up on all the news. That being said there are a couple of points I can make that are essentially the frame I will use to look at the recent news. […]

July 7 Biotech Update

The sector seems to be consolidating its previous move although the broader market does not necessarily look that strong. That being said the trend for the sector is higher and outperformance at least in the recent past. I still expect it to test the breakout level at which point everyone will be expecting the levels […]

June 22 Biotech Update

The sector continues to rocket higher as clearly sentiment has reversed. This run likely has more legs than anyone thinks. The sector has been in a massive bear market and churned sideways for about 18 months. We were barely 5% above the upper end of the range and I saw comments about the sector looking […]

June 7 Biotech Update

I want to focus on a couple of specific companies in more detail over the next couple of days. There seems to have been a couple of irrational reactions to ASCO news and it is important to understand why they are irrational. Of course, it could be that I am wrong but I will try […]

June 6 Biotech Update

I am back from ASCO with a lot to cover and I will focus on broader themes today and spend the rest of the week with more company specific commentary. The reaction to ASCO so far has been bad but as I noted before that is not completely unexpected. The trading action before ASCO does […]

June 1 Biotech Update

The sector sort of had some positive news yesterday with TSRO putting itself on the proverbial block. This obviously moved TSRO and sector as it reminded people that good things might happen as well. Given that this was meaningful for the sector (and the lack of other news) I want to focus on a couple […]

May 30 Biotech Update

It is ASCO week and the end of a long Memorial Day weekend and there is no news. Usually heading into long weekends there is the expectation/hope that a deal can be finished. Unsurprisingly there are no deals but perhaps a little surprising last week ended with no real excitement or talk of a deal. […]

May 4 Biotech Update

It looks like a vote is set for TrumpCare in the House and while it will be close I lean towards it passing. Congress is heading towards a recess so I suspect many republicans are going to vote to give Trump a win. It is a low cost vote as it will not pass the […]

May 1 Biotech Update

This week has another batch of earnings that will likely drive sentiment and price action. So far it seems like the sector is more or less trading in line with the market but perhaps slightly better. There is still some follow up from last week to talk about and one big earning tomorrow. 1. When […]

March 22 Biotech Update

We finally had a 1%+ down day in the market, so we can finally stop seeing on the tweets about how long it has been since a 1% sell off. This broader market weakness led to sector weakness- not surprisingly. Of course, this is right after Trump made another comment on drug pricing, so this […]

March 13 Biotech Update

Certainly getting some more news and events that could be driving the sector but nothing really thesis changing, we need to wait for the end of the week with the PCSK9 data. As we wait for that data, there are some interesting notes and company specific information that we can talk about. 1. KPTI was […]

January 9 Biotech Update

I am getting ready to head out to JPM but I wanted to have a quick JPM note this morning. In general, the news has been a little slow as compared to expectations but certainly bullish. I will highlight a couple of the more important stories. 1. We have almost $6B in deals in one […]